GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Cyclically Adjusted PB Ratio

Rosetta Genomics (Rosetta Genomics) Cyclically Adjusted PB Ratio : (As of May. 23, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Rosetta Genomics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Rosetta Genomics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Cyclically Adjusted PB Ratio Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rosetta Genomics's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Rosetta Genomics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Cyclically Adjusted PB Ratio falls into.



Rosetta Genomics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Rosetta Genomics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2017 is calculated as:

For example, Rosetta Genomics's adjusted Book Value per Share data for the three months ended in Jun. 2017 was:

Adj_Book=Book Value per Share/CPI of Jun. 2017 (Change)*Current CPI (Jun. 2017)
=0.425/103.3491*103.3491
=0.425

Current CPI (Jun. 2017) = 103.3491.

Rosetta Genomics Quarterly Data

Book Value per Share CPI Adj_Book
200512 -774.333 83.032 -963.805
200603 0.000 84.298 0.000
200606 0.000 85.606 0.000
200609 0.000 85.606 0.000
200612 675.274 85.142 819.681
200703 2,151.401 86.640 2,566.307
200706 2,025.258 87.906 2,381.053
200709 1,910.194 87.964 2,244.286
200712 1,427.146 88.616 1,664.413
200803 1,200.845 90.090 1,377.585
200806 993.361 92.320 1,112.029
200809 896.017 92.307 1,003.203
200812 952.663 88.697 1,110.031
200903 754.793 89.744 869.217
200906 677.146 91.003 769.011
200909 519.818 91.120 589.585
200912 345.905 91.111 392.366
201003 404.637 91.821 455.440
201006 208.219 91.962 234.002
201009 30.933 92.162 34.688
201012 -53.061 92.474 -59.301
201103 137.554 94.283 150.781
201106 82.450 95.235 89.475
201112 -6.092 95.213 -6.613
201206 17.425 96.819 18.600
201212 40.763 96.871 43.489
201306 34.142 98.518 35.816
201312 27.086 98.326 28.470
201406 21.236 100.560 21.825
201409 0.000 100.428 0.000
201412 15.369 99.070 16.033
201503 0.000 99.621 0.000
201506 16.404 100.684 16.838
201509 13.884 100.392 14.293
201512 11.476 99.792 11.885
201603 9.100 100.470 9.361
201606 7.275 101.688 7.394
201609 5.129 101.861 5.204
201612 2.396 101.863 2.431
201706 0.425 103.349 0.425

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rosetta Genomics  (OTCPK:ROSGQ) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Rosetta Genomics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (Rosetta Genomics) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Executives
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd. 10 percent owner C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458